Gene therapy of neurodegenerative disorders K K Jain MD ( Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose. ) Originally released December 16, 1997; last updated August 14, 2016; expires August 14, 2019 Introduction Overview This article describes gene therapy of various neurodegenerative disorders: Parkinson disease, Alzheimer disease, Huntington disease, and amyotrophic lateral sclerosis. Some of these are in clinical trials. Parkinson disease is an ideal candidate. The introduction of functional genes into the brain of patients with Parkinson disease may, for example, prove useful as a means to replace a defective gene, introduce a potentially neuroprotective or neurorestorative protein, or permit the physiological delivery of a deficient neurotransmitter. Potential gene therapy approaches to Alzheimer disease are based on neurotrophic factors and not neurotransmitters. The optimal method of gene therapy is ex vivo involving implantation of genetically engineered cells secreting nerve growth factor. A clinical trial for amyotrophic lateral sclerosis was conducted with implantation of genetically modified cells. Historical note and terminology Gene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state. Carriers or delivery vehicles for therapeutic genetic material are called vectors, which are usually viral, but several nonviral techniques are being used as well. Gene therapy usually implies the introduction of altered genes into the body of a patient instead of just the products of cells with altered genes. The term "genetic engineering" applies to the genetic manipulation of living cells, as well as implantation of genetically engineered cells into the living body, and can be considered as a form of gene therapy. Neurosurgeons refer to gene therapy as "cellular and molecular" neurosurgery. The history and basics of gene therapy are described in the article providing an introduction to gene therapy. Gene therapy of Parkinson disease, Alzheimer disease, Huntington disease, and amyotrophic lateral sclerosis will be described in this article. RNA interference (RNAi)-based techniques, which can be employed to reduce expression of specific genes, hold great promise as therapy for these types of neurodegenerative disorders (Maxwell 2009). Clinical aspects Description Vectors for gene therapy of neurodegenerative disorders. A variety of viral as well as nonviral vectors are available. Adeno-associated virus (AAV) vectors are particularly useful for neurodegenerative diseases and have been used in preclinical studies as well as in human clinical trials. An efficient and reliable method for the production and purification of AAV serotype 2 vectors for both in vitro and in vivo applications has been described (Morgenstern et al 2011). Techniques of gene therapy for Parkinson disease. Gene therapy for Parkinson disease is considered to be the most important potential application of the technology to neurologic disorders. A classification of various gene therapy techniques applicable to Parkinson disease is shown in Table 1. Table 1. Gene Therapy Techniques Applicable to Parkinson Disease In vivo. Vector-mediated direct transfer of genetic material to cerebral target cells.
Viral vectors Herpes simplex virus-1 vectors with tyrosine hydroxylase gene. Adenoviral vector with glial cell line-derived neurotrophic factor gene. Direct striatal delivery of L-dopa using recombinant adeno-associated viral vectors. AAV vector with glial cell line-derived neurotrophic factor gene. AAV or lentiviral vector for the parkin gene transfer. Lentiviral gene transfer of a modified Neurturin construct. Adenoviral-mediated transfer of genes encoding proteins that produce the inhibitory transmitter gamma-aminobutylic acid in the subthalamic nucleus, suppressing its hyperactivity. AAV vector with human aromatic L-amino acid decarboxylase (haadc) gene. Non-viral vectors: plasmid DNA-lipofectin complex Ex vivo. Genetic manipulation of cultured cells in vitro and transplantation into the brain. Fibroblasts (3T3) producing: Tyrosine hydroxylase. glutamyl transpeptidase cyclohydroxylase-1. Combination of tyrosine hydroxylase and glutamyl transpeptidase cyclohydroxylase-1. Glial cell line-derived neurotrophic factor. Basic fibroblast growth factor. Neurturin (homolog of glial cell line-derived neurotrophic factor). Multiple neurotrophic factors: glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor. Myoblasts producing tyrosine hydroxylase Pancreatic endocrine cells producing tyrosine hydroxylase Astrocytes producing: L-3,4-dihydroxyphenylalanine. Brain-derived neurotrophic factor. Transplantation of astrocytes containing a tyrosine hydroxylase gene. Transplantation of neural stem cells transduced with tyrosine hydroxylase gene Herpes simplex virus-1 vectors in Parkinson disease. The most relevant vector of this category is a defective herpes simplex virus-1 vector containing a gene encoding human tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. A number of studies have shown that augmenting the activity of tyrosine hydroxylase will increase levodopa and subsequent dopamine production, as well as its release into the extracellular fluid compartment, bypassing the dopaminergic nigral afferent input. This would provide a more physiological dopamine delivery than is possible with any of the other methods described in the previous section. A schematic effect of tyrosine hydroxylase gene delivery on dopamine levels is shown. Long-term (1 year) behavioral and biochemical recovery has been demonstrated in parkinsonian rats by a herpes simplex virus vector expressing tyrosine hydroxylase. Later work by the same authors showed that genetically engineered cells transplanted into the brains of monkeys caused a 40% improvement in the symptoms of neurotoxininduced parkinsonism. A criticism of this work was that striatal injection of a gene-delivery herpes amplicon system can damage the neurons and cross synapses in the striatum. One explanation that has been offered for the improvement of parkinsonism is that it is due to surgical intervention involved in cell transplantation rather than due to alteration of specific function by the gene delivery. This explanation is unlikely because the damage around the site of injection of the vector is limited, and improvement is not seen with implantation of the vector without tyrosine hydroxylase gene in control animals. A complimentary approach to transmitter enzyme replacement is the strategy to alter the function of surviving dopaminergic neurons and improve dopaminergic transmission. The key mediators in these pathways are signaltransduction proteins. Defective herpes simplex virus-1 vectors containing genetic sequences encoding catalytic domains of adenylate cyclase, protein kinase C, and calcium calmodulin protein kinase 2 can direct the stable expression of these enzymes. Nigrostriatal cells can be specifically targeted by using a combination of stereotactic surgery directed at substantia nigra with further cell specificity, which is obtained by using the tyrosine hydroxylase promoter driving the expression of a signal-transduction enzyme. Adeno-associated virus vectors in Parkinson disease. An adeno-associated virus vector (AAVgdnf) has been developed that contains the cdna for glial cell line-derived neurotrophic factor. AAVgdnf introduced unilaterally prior to 6-hydroxydopamine administration results in neuroprotection in a rat model of Parkinson disease.
A bicistronic construct, AAVthIRESaadc, which contains both the human tyrosine hydroxylase and AADC genes, has also been tested. AADC is responsible for the conversion of levodopa to dopamine in dopaminergic neurons. Elevated levels of dopamine could be demonstrated near injection tracts following the intrastriatal injection of bicistronic vector in MPTP-treated monkeys. Convection-enhanced, MRI-guided delivery of an AAV vector with human AADC gene bilaterally to the putamen has been completed in a phase I trial in Parkinson disease patients (Valles et al 2010). PET uptake correlated with haadc transgene expression and confirmed the findings of T2 hyperintensity on MRI and haadc immunohistochemistry. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson disease using AAV2-hAADC vector has shown stable transgene expression over 4 years after vector delivery and continued safety (Mittermeyer et al 2012). A gene therapy candidate consisting of the GDNF gene carried by an AAV-2 vector has been granted FDA approval to enable the start of clinical trials. Adenovirus vectors in Parkinson disease. A recombinant adenovirus vector expressing tyrosine hydroxylase, administered by intracerebral injection in the 6-hydroxydopamine rodent model of Parkinson disease, decreases rotational asymmetry. Adenoviral-mediated glial cell line-derived neurotropic factor injection into the rat striatum was shown to reduce loss of dopamine neurons. In another study, adenoviral mediated glial cell line-derived neurotropic factor injected into the 6-hydroxydopamine rat model of Parkinson disease not only prevented dopaminergic neuronal degeneration but also improved motor function. These studies indicate that similar benefits may occur in patients with Parkinson disease. A tropism-modified adenovirus5 vector that contains the fiber knob domain from canine adenovirus serotype 2 has been constructed, and delivery to the substantia nigra or striatum showed that this vector produced a neuronally restricted pattern of gene expression (Lewis et al 2014). Besides precise control of transgene expression, this vector can be further developed to be a high-capacity vector, which can maintain transgene expression in the CNS for over a year. Targeted stereotactic delivery to substantia nigra or striatum is possible for enabling clinical trials in human patients. Lentiviral vectors. These vectors have been used to carry the cdna for neublastin (a neurotrophic factor of GDNF family). Neuroprotective effect has been reported following injection of these vectors into the striatum and ventral midbrain of animal models of Parkinson disease (Fjord-Larsen et al 2005). Plasmid DNA-lipofectin complex. Plasmid-DNA-transfected brain cells can generate levodopa locally in the striatum in quantities sufficient to partially compensate for loss of intrinsic striatal dopaminergic input. Controlled and prolonged delivery of genes in vivo is possible by direct intracerebral tyrosine hydroxylase and L-amino acid decarboxylase gene transfer with injection of plasmid DNA-liposome complex. Injection of such a gene construct into striatum of a rat model of Parkinson disease can lead to expression of tyrosine hydroxylase. Novel vector system. As an aid in the development of vector systems for use in gene therapy paradigms of CNS disorders such as Parkinson disease, L-Dopa or dopamine-producing gene cassettes have been developed. Specifically, a human tyrosine hydroxylase cdna (HTH-2) is rendered constitutively active by truncation of the N-terminal regulatory domain. In addition, a bicistronic construct capable of directing the production of dopamine is created by inserting an internal ribosome entry site downstream of N-terminal regulatory domain followed by the coding sequences of aromatic amino acid decarboxylase. All 3 constructs generated immunoreactive peptides of the predicted size, were enzymatically active, and produced L-Dopa (HTH-2, N-terminal regulatory domain) or dopamine (bicistronic construct) following transient transfection of COS-7 cells. These constructs, in conjunction with viral or nonviral expression systems, may be efficacious in gene therapy approaches to Parkinson disease. Regulatable systems enable the expression of the introduced gene to be adjusted or stopped by changing the dose of an oral inducer drug and provide an ideal method for safely delivering effective, flexible gene therapy treatments over the long course of Parkinson disease (Cress 2008). Multiple gene therapy. In a rat model of Parkinson disease, the efficiency of adeno-associated viral vector-mediated gene therapy using 3 genes--tyrosine hydroxylase gene, aromatic L-amino acid decarboxylase gene and GTP cyclohydrolase I gene--was shown to be significantly better than that of single gene therapy (Lu et al 2004). Multiple gene therapy may be useful in cases where the damage to the dopaminergic system is too advanced to be corrected by single gene therapy.
Ex vivo gene therapy of Parkinson disease using genetically engineered cells. Various cells have been used for ex vivo gene therapy of experimental Parkinson disease. Differences between direct gene transfer into striatal cells and cell transplantation (grafting) are: Graft cells are localized and the diffusion of dopamine is retarded by extracellular matrix secreted from the graft, whereas gene transfer delivers tyrosine hydroxylase gene to relatively widespread cells without production of extracellular matrix. Graft cells contain dopamine transporters that can result in reuptake of dopamine, thereby diminishing the diffusion of dopamine. In contrast, direct gene transfer into nondopaminergic striatal cells should not add any dopamine transporters to the striatum, and diffusion of dopamine can continue unimpeded by dopamine transporters. Some of the ex vivo approaches are described briefly here: Fibroblasts. A well-established experimental approach uses fibroblasts transduced with retroviral vectors encoding the human tyrosine hydroxylase 2 and human glutamyl transpeptidase cyclohydrolase 1 genes. This results in an increase of levodopa production, but no improvement of symptoms have been demonstrated. Fibroblasts, even though they do not integrate with the brain, are preferred cells for implantation because they remain where they are inserted and their location can be verified by a suitable marker and positron emission tomography scanning. Bone marrow stromal cells. These can be transduced by retroviral vectors to produce levodopa. Intrastriatal injection of such vectors into 6-hydroxydopamine lesioned rats leads to engraftment and dopamine production. Astrocytes. When genetically engineered by viral vector-mediated tyrosine hydroxylase gene transfer, astrocytes secrete high levels of levodopa. Astrocytes can also be engineered to produce brain-derived neurotrophic factor. The efficacy of a technique for expressing GDNF exclusively in astrocytes was evaluated in the mouse MPTP model of Parkinson disease (Drinkut et al 2012). The efficacy was equal to that of neuron-derived GDNF, but this technique was safer as unilateral striatal GDNF expression in astrocytes did not result in delivery of GDNF to the contralateral hemispheres as was the case when GDNF was expressed in neurons. Astrocytes, transfected with an adenoviral vector encoding human tyrosine hydroxylase under the negative control of a tetracycline-based regulatory system, can synthesize large amounts of tyrosine hydroxylase and synthesize levodopa as shown in vitro, and have the potential for transplantation for Parkinson disease. Because they integrate with brain tissues, astrocytes are promising material for the gene therapy approach to Parkinson disease. However, a potential drawback is that that these cells wander off in the brain after implantation, and it is difficult to predict their final location. Genetically engineered cells producing neurotrophic factors. The basic fibroblast growth factor is known to enhance the survival of dopaminergic neurons in vitro. Cells that have been genetically modified to produce basic fibroblast growth factor can improve the functional efficacy of dopaminergic neurons following implantation in the brains of animal models of Parkinson disease. Interest has also been focused on the development of proliferating cell lines for transplantation that can be genetically manipulated to produce other neurotrophic factors. Cells for transplantation can also carry genes for dopamine-synthesizing enzymes. Stem cells. Neural stem cells are transduced with tyrosine hydroxylase and glutamyl transpeptidase cyclohydroxylase 1 genes, which produce important enzymes in dopamine biosynthesis and can be successfully transplanted into the brains of rat models of Parkinsonian disease (Ryu et al 2005). Marrow stromal cells can be transfected with tyrosine hydroxylase gene by an adeno-associated virus vector and transplanted into the striatum of rat model of Parkinson disease (Lu et al 2005). Glutamic acid decarboxylase (GAD) gene therapy. Glutamic acid decarboxylase delivered by an adenoassociated virus vector (NLX-P101, Neurologix, Inc.) was shown to be a safe and efficient method of reducing motor deficits in a primate model of Parkinson disease. As glutamic acid decarboxylase potentiates inhibitory neurotransmission from the subthalamic nucleus, sustained expression of glutamic acid decarboxylase in the nucleus by direct delivery of NLX-P101 is an explanation of the beneficial effects (Diaz-Nido 2010). Delivery of parkin gene. Mutations in parkin gene have been linked to familial Parkinson disease. The loss of parkin's E3-ligase activity leads to dopaminergic neuronal degeneration in early-onset autosomal recessive juvenile parkinsonism, suggesting a key role of parkin for dopamine neuron survival. Animals overexpressing parkin showed
significant reductions in alpha-synuclein-induced neuropathology, including preservation of tyrosine hydroxylasepositive cell bodies in the substantia nigra and sparing of tyrosine hydroxylase-positive nerve terminals in the striatum. Overexpression of parkin has complementary effects to those described with use of neurotrophic factors for Parkinson disease (Ulusoy and Kirik 2008). Adeno-associated virus-mediated parkin gene therapy has been shown to be effective against alpha-synucleinopathy, suggesting its potential suitability for patients with Parkinson disease (Yamada et al 2005; Mochizuki 2007). Targeting alpha-synuclein gene expression by RNA interference. Overexpression of wild-type alpha-synuclein is considered to confer susceptibility to Parkinson disease (Yamada et al 2004). Use of short interfering RNAs to target and knock down alpha-synuclein gene expression has been shown to be feasible in animal experimental studies and has the potential for developing therapeutics to treat Parkinson disease. Another approach is in vivo transfer of genes encoding beta-synuclein, the nonamyloidogenic homologue of alpha-synuclein, which binds to alpha-synuclein, reducing its aggregation and accumulation in the synaptic membrane (Hashimoto et al 2004). This might be an alternative gene therapy approach for Parkinson disease. Prospects of gene therapy for Parkinson disease. The technique of direct delivery of the vector to the striatum or substantia nigra is a standard neurosurgical procedure. However, for the diffuse neurologic manifestations of Parkinson disease, global delivery of the vector to the brain may be preferred. Intraventricular delivery has also been tried and may result in preferential expression in ependymal and circumventricular tissues. Among the ex vivo approaches, the most important is implantation of genetically engineered cells releasing neurotrophic factors (protective and regenerative) and among the in vivo approaches is the delivery of tyrosine hydroxylase gene (neurotransmitter restoration). The ideal approach may be a combination of these 2 therapies. RNA interference can theoretically be applied to Parkinson disease because overexpression of various proteins is known to kill the dopamine neurons of the substantia nigra (Manfredsson et al 2006). RNA interference has been combined with lentiviral vector-based gene therapy to turn off alpha-synuclein in dopamine neurons. By using a dual cassette lentivirus that coexpresses an alpha-synuclein-targeting short hairpin RNA, it was possible to deliver the RNAi to the brain of rats and turn off the alpha-synuclein protein in neurons (Sapru et al 2006). This technique has the potential for clinical development of Parkinson disease treatment. Clinical trials of gene therapy for Parkinson disease. Several approaches have been used in clinical trials for gene therapy of Parkinson disease: (1) augmentation of dopamine levels via increased neurotransmitter production (2) modulation of the neuronal phenotype (3) neuroprotection (4) lentiviral system encoding multiple genes. The first 2 therapies focus on increasing dopamine production via direct delivery of genes involved in neurotransmitter synthesis (amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase 1). In an attempt to bypass the degenerating nigrostriatal pathway, another approach uses adeno-associated viral vectors to deliver glutamic acid decarboxylase to the subthalamic nucleus, converting a subset of excitatory neurons to GABA-producing cells. The third approach is aimed at protecting the degenerating nigrostriatum by striatal delivery of adeno-associated viral vectors harboring the neuroprotective gene, neurturin, aiming to slow disease progression by enhancing neuronal survival. The fourth approach involves an equine infectious anemia virus-based lentiviral system encoding amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I in a single transcriptional unit (Nakata et al 2012). Several clinical trials of gene therapy for Parkinson disease have been conducted during the past decade. Currently, 26 clinical trials are registered on the US Government clinical trials web site: https://clinicaltrials.gov. The first in vivo gene therapy for Parkinson disease was administered to the brain of a patient in 2003 at a medical center in New York. The therapy delivered the glutamic acid decarboxylase (GAD) gene (NLX-P10) using an adenoassociated viral vector via 90-minute infusion to a target identified by CT scan and MRI. A phase 1 clinical trial of AAV- GAD gene therapy delivered to the subthalamic nucleus has shown that the procedure is safe and well tolerated by patients with advanced Parkinson disease (Kaplitt et al 2007). A double-blind phase 2 trial completed all the surgical procedures in 2009.
In 2006, an open-label phase 1 study was conducted in which advanced Parkinson disease patients underwent stereotactic neurosurgery to deposit an adeno-associated viral vector carrying the gene for the neurotrophic factor neurturin (CERE-120, Ceregene, Inc.) into their putamen. The patients tolerated the treatment well and had reduction of symptoms by approximately 40% as measured by the Unified Parkinson's Disease Rating Scale motor off score. The study is proceeding to a randomized phase-2 study that will gather more detailed data on both safety and efficacy with brain imaging studies. Although safety of the procedure was shown, there is no publication yet about the final results. In another clinical trial, patients with moderately advanced Parkinson disease received bilateral intraputaminal infusion of an adeno-associated viral type 2 vector (AAV2) containing the gene for human aromatic L-amino acid decarboxylase (AADC), the enzyme that converts levodopa into dopamine (Christine et al 2009). The gene therapy resulted in improvements of scores of motor scales and was well tolerated, but intracranial hemorrhages followed the operative procedure in 3 of 10 patients in the study. An open-label phase 1 safety and efficacy study that started in August 2016 is testing AAV2-hAADC administered by MRI-guided convective infusion into the putamen of subjects with Parkinson disease who have fluctuating responses to levodopa (NCT01973543). Results of a phase II trial to evaluate gene therapy in patients on levodopa therapy, which was designed to deliver key enzymes involved in the synthesis of dopamine by a lentiviral vector bilaterally in the putamen, showed that it was safe and effective with improvement in motor behavior in all patients (Palfi et al 2014). Data from clinical trials suggest that gene therapy targeting multiple brain regions including the striatum and substantia nigra can be safe and well tolerated in Parkinson disease patients (Allen and Feigin 2014). There are still challenges, including how to modulate gene expression and how to determine the optimal target, dose, and selection of patient population for study in future gene therapy trials. Analyses of autopsied brains from subjects previously administered AAV2-neurturin gene transfer in clinical trials indicate that optimizing the effects of neurotrophic factors in Parkinson disease likely requires delivery to both the degenerating cell bodies in substantia nigra and their terminals in striatum (Bartus et al 2011). Experiments in animal models indicate that high-dose delivery to substantia nigra was responsible for weight loss seen as an adverse effect. A low dose of neurturin delivered with the modified technique in ongoing clinical trials is expected to be safer. Gene therapy for Alzheimer disease. Retroviral vectors have been used to genetically modify primary autologous primate fibroblasts ex vivo to produce and secrete nerve growth factor. These cells were then grafted to the basal forebrain region of adult rhesus monkeys after fornix transection. Cholinergic neuronal degeneration could be prevented for extended periods in vivo; this method has the potential to be a treatment for Alzheimer disease. A phase I clinical trial of Alzheimer disease uses adeno-associated viral vector. Preventive gene therapy with nerve growth factor might be useful for persons at high risk of developing Alzheimer disease. One advantage of this approach is that it provides a method for selective delivery of therapeutic genes and their products to afflicted areas of the brain. Lentiviral vectors engineered to overexpress the glial cell-derived neurotrophic factor (GDNF) gene in hippocampal astrocytes of 3xTg-AD mice in vivo were shown to be safe and effective, both as a potential gene therapy as well as a tool to uncover the mechanisms of GDNF neuroprotection in Alzheimer disease (Revilla et al 2014). As in the case of other neurodegenerative disorders, it is possible that gene therapy can be combined with systemic cholinomimetic therapy. If amyloid deposit is considered to be a primary event, it will provide a strong rationale to target amyloid deposits for therapeutic intervention. Several amyloid-based approaches are in the preclinical stage and are expected to advance to clinical trials in the next few years. In one of these projects, transgenic neurons expressing human Bcl-2 were partially protected against amyloid beta-peptide-induced neuronal death. This neuroprotection appears to be related to the complete inhibition of apoptosis induced by both amyloid beta-peptides, which can form the basis of gene therapy for Alzheimer disease. Genetically engineered cells producing nerve growth factor when implanted into basal cerebral structures have been shown to reverse cognitive changes associated with aging in rhesus monkeys. Aging is associated with a significant 25% reduction in cortical innervation by cholinergic systems in rhesus monkeys and this was restored by nerve growth factor. These findings are relevant to potential clinical use of nerve growth factor in Alzheimer disease. Postmortem
examination of brains from Alzheimer disease patients treated in clinical trials of nerve growth factor (NGF) gene therapy and survived for 1 to 10 years showed that neurons exhibiting tau pathology, as well as neurons free of tau, expressed NGF, indicating that degenerating cells can be infected with therapeutic genes, with resultant activation of cell signaling (Tuszynski et al 2015). Clinical trials of gene therapy in Alzheimer disease. As of August 2016, 22 clinical trials of gene therapy for Alzheimer disease are listed on the U.S. Government website: https://clinicaltrials.gov. Only 4 of these trials actually involve gene therapy according to the definition of this term. Two of the 4 have been completed, and information is insufficient on the other 2 trials. The implementation of clinical testing of nerve growth factor therapy for Alzheimer disease has been limited by the dual need to achieve adequate concentrations of this neurotrophic factor in specific brain regions containing degenerating neurons and prevent growth factor spread to nontargeted regions to avoid adverse effects (Tuszynski 2007). The current status of a phase II trial of adeno-associated virus delivery of nerve growth factor by intracerebral injection is unknown (NCT00876863). Neprilysin gene therapy. Neprilysin, a substance naturally found in the brain, alters amyloid beta proteins in ways that lead to their destruction. A form of gene therapy appears to reduce amyloid beta in the brains of mice with Alzheimer disease pathology by increasing brain levels of neprilysin. One study concluded that overexpression of neprilysin by a gene therapy approach in areas vulnerable to amyloid beta aggregation in Alzheimer disease brain may protect the neurons from the toxic effects of this peptide (El-Amouri et al 2007). However, some challenges of neprilysin gene therapy include secondary toxicity, activation of the immune response, and low efficiency (Li et al 2015). Therefore, safe and efficient neprilysin delivery systems with high transfection efficiency are needed gene therapy of Alzheimer disease. Fibroblast growth factor (FGF) gene therapy. FGF2 gene was delivered bilaterally to the hippocampi of mouse models of Alzheimer disease via an AAV2/1 vector, resulting in significantly improved spatial learning as well as clearance of amyloid beta peptides from the hippocampi (Kiyota et al 2011). This method has potential as an alternative therapy of Alzheimer disease and possibly other neurocognitive disorders. RNAi-based therapy for Alzheimer disease. Cyclin-dependent kinase 5 (CDK5) is a key mediator of tau hyperphosphorylation and neurofibrillary pathology. Use of RNAi for CDK5 silencing has been proposed as a targeted and specific therapeutic alternative for Alzheimer disease (López-Tobón et al 2011). Development of gene therapy for Huntington disease. So far no clinical trial of gene therapy has been conducted for Huntington disease, but the following methods are under investigation: Encapsulated genetically engineered cellular implants. Implants of encapsulated recombinant human ciliary neurotrophic factor-producing fibroblasts have been shown to prevent behavioral deficits and striatal degeneration in a rodent model of Huntington disease. Other neurotrophic factors have been shown to protect vulnerable striatal neurons in animal models of Huntington disease. The mechanisms of protection and prevention of behavioral deficits are complex and unrelated to the trophic factor binding to its receptor. For example, cells genetically modified to secrete nerve growth factor or ciliary neurotrophic factor protect degenerating striatal neurons that do not express receptors for these factors. A phase I study has evaluated the safety of intracerebral administration of ciliary neurotrophic factor in subjects with Huntington disease, using a device formed by a semipermeable membrane encapsulating a cell line engineered to synthesize ciliary neurotrophic factor (Bloch et al 2004). No sign of ciliary neurotrophic factor-induced toxicity was observed. Viral vector mediated administration of neurotrophic factors. Neuroprotective effect of a ciliary neurotrophic factorexpressing lentiviral vector was demonstrated in a rat model of Huntington disease. Lentiviral-mediated tetracyclineregulated gene transfer is feasible in the brain, and this vector has been used to investigate the dose-dependent neuroprotective effect of human ciliary neurotrophic factor in the quinolinic acid model of Huntington disease. Adeno-associated viral-mediated gene transfer of glial cell line-derived neurotrophic factor into the striatum provides neuroanatomical and behavioral protection in a rodent model of Huntington disease. Further studies in mouse models
support the concept that viral vector delivery of glial cell line-derived neurotrophic factor may be a viable treatment for patients suffering from Huntington disease (McBride et al 2006). Antisense therapy for Huntington disease. Modified 2'-O-methyl phosphorothioate triplet-repeat antisense oligonucleotides have been shown to effectively reduce mutant huntingtin transcript and protein levels in patientderived Huntington disease fibroblasts and lymphoblasts (Evers et al 2011). RNA interference therapy (RNAi) of Huntington disease. This method, based on blocking expression of mutant huntingtin gene, is a promising therapeutic strategy. A high-capacity adenoviral vector, expressing a short hairpin RNA targeted to exon 1 of the huntingtin gene, was shown to efficiently inhibit huntingtin expression in neuronal and nonneuronal cell lines (Huang et al 2007). These finding support further development of this technique in animal models. Intraventricular infusion of single-stranded (ss) sirna produced selective silencing of the mutant huntingtin (HTT) allele throughout the brain in a mouse model of Huntington disease (Yu et al 2012). These results demonstrate that chemically modified ss-sirnas, functioning through the RNAi pathway, provide allele-selective compounds for clinical development. Technique of gene therapy of amyotrophic lateral sclerosis. Various neurotrophic factors have been administered using genetically engineered cells. Neurotrophic factor genes may be transduced using viral vectors. Currently, no active trial of gene therapy for amyotrophic lateral sclerosis is in progress. Ciliary neurotrophic factor. Only 1 trial has been conducted with gene therapy; it involved intrathecal implantation of polymer-encapsulated genetically engineered cells by CRIBTM secreting recombinant human ciliary neurotrophic factor (Aebischer et al 1996). In this phase 1 study, 6 patients with amyotrophic lateral sclerosis received genetically modified ciliary neurotrophic factor-secreting baby hamster cells via CRIBTM introduced into the lumbar intrathecal space. These cells were capable of secreting 1.0 µg of human ciliary neurotrophic factor per day and nanogram levels of ciliary neurotrophic factor were measured in the patients' CSF for at least 17 weeks posttransplantation. Prior to this treatment, ciliary neurotrophic factor was not detectable in the CSF of these patients. This study demonstrated for the first time that significant and measurable doses of neurotrophic factors can be delivered by this approach without the deleterious side effects observed with peripheral administration. This study also demonstrated the pharmacological dose control of a neurotrophic factor by gene therapy; the authors have suggested further clinical trials with multiple neurotrophic factors using this method of delivery. The results were satisfactory and phase 2 studies are planned. Use of multiple neurotrophic factors will be considered. Gene therapy is anticipated to be used mainly in the form of genetically engineered encapsulated cells for the in vivo production and delivery of neurotrophic factors. Because of the multifactorial pathogenesis of amyotrophic lateral sclerosis, various combination therapies are foreseen; administration of neurotrophic factors by gene therapy may be combined with riluzole. Glial cell line-derived neurotrophic factor. Using retroviral vectors, myoblasts have been genetically modified to secrete glial cell line-derived neurotrophic factor. Use of these myoblasts has prolonged the onset of disease and delayed deterioration in mouse models of familial amyotrophic lateral sclerosis. Glial cell line-derived neurotrophic factor gene therapy in mouse models of familial amyotrophic lateral sclerosis promote the survival of motoneurons, suggesting that a similar approach might delay the progression of neurodegeneration of amyotrophic lateral sclerosis. Adeno-associated virus-mediated glial cell line-derived neurotrophic factor delivery to the muscle is a promising means of gene therapy for amyotrophic lateral sclerosis. Vascular endothelial growth factor. Vascular endothelial growth factor has been implicated in neuroprotection and has a therapeutic potential for the treatment of amyotrophic lateral sclerosis. A single injection of a vascular endothelial growth factor-expressing lentiviral vector into various muscles delayed onset and slowed progression of amyotrophic lateral sclerosis in mice engineered to overexpress the gene coding for the mutated form of the superoxide dismutase- 1 (Azzouz et al 2004). This method has not been developed further. Adenoviral-mediated transfer of neurotrophic factors for amyotrophic lateral sclerosis. Pretreatment with brain-derived neurotrophic factor or glial cell-line derived neurotrophic factor using adenovirus-mediated gene transfer by intramuscular injection has been shown to prevent the massive death of motor neurons that normally follows axotomy in the neonatal period. Another study using adenoviral-mediated transfer of brain-derived neurotrophic factor or ciliary neurotrophic factor into the lesioned nerves showed that survival of axotomized motor neurons was maintained for at
least 5 weeks in rats. However, overexpression of muscle-derived neurotrophin-3, although it prevented degeneration of axons at motor end plates, had little effect on the number of motor neuron cell bodies in a murine model of motor neuron disease. Techniques suitable for tonic exposure to both nerve and muscle-derived neurotrophic factors may have implications for the design of future therapeutic strategies. Advances in gene transfer techniques may enable transduction of sufficient numbers of cerebral, brainstem, and spinal cord neurons for therapeutic applications. It may be possible to repopulate lost corticospinal and lower motor neurons by transplanting stem cells or stimulating native progenitor populations. Retrograde delivery of gene therapy for amyotrophic lateral sclerosis. Although chronic delivery of molecules to the CNS is difficult, an adeno-associated virus can be retrogradely transported efficiently from muscle to motor neurons of the spinal cord after intramuscular delivery. Insulin-like growth factor 1-AAV complex, when injected intramuscularly, prolongs life and delays disease progression in mouse models of amyotrophic lateral sclerosis. Use of lentiviral vectors for gene therapy of amyotrophic lateral sclerosis. Numerous studies in animal models have shown that lentiviral vectors are suitable for gene therapy of neurodegenerative diseases such as amyotrophic lateral sclerosis (Nanou and Azzouz 2009). RNAi therapy for amyotrophic lateral sclerosis. RNAi, using recombinant adenovirus and AAV2 vectors, has been tested in a transgenic mouse model that overexpresses mutant Cu, Zn superoxide dismutase and causes amyotrophic lateral sclerosis by a gained toxic property (Wu et al 2009). Nerve injection of viral vectors efficiently transferred transgenes into motor neurons with modest therapeutic efficacy. Prevention of the progression of degenerative processes. Regeneration of the damaged CNS. Replacement of neurotransmitter deficiency in neurodegenerative disorders. Indications Indications for gene therapy of neurodegenerative disorders are mainly for the following conditions: Alzheimer disease Amyotrophic lateral sclerosis Huntington disease Parkinson disease The techniques are mostly in preclinical development. Clinical trials are also in progress and most of these are relevant to Parkinson disease. Criteria for patient selection are determined for each clinical trial. Contraindications No contraindications have been identified. Results Most of the gene therapy experiments done in animal models have demonstrated the safety and efficacy of gene therapy. Clinical trials in humans are in early stages and have demonstrated safety, but efficacy requires long-term, later-stage clinical trials. Adverse effects Adverse effects of gene therapy are described in the article on gene therapy techniques. Special considerations Gene therapy can be carried out safely during pregnancy, but neurodegenerative diseases covered in this article do not usually occur during pregnancy. Scientific basis Rationale of gene therapy for Parkinson disease. This remains to be the most important area for development of gene therapy for neurologic disorders. Parkinson disease is an ideal candidate; the neurologic abnormalities are known to result from the degeneration of dopaminergic neurons and nigrostriatal pathways. Clinical signs of the disease can be ameliorated by the replacement of levodopa. The availability of well-characterized animal models facilitates the
evaluation of gene therapy. Discovery of a genetic locus for Parkinson disease is a big step in our understanding of the disease, even though there may be no genetic contribution or multiple genes involved in the majority (98%) of patients with Parkinson disease. Several problems, however, need to be addressed. These include the following: Long-term expression (several months) has not been demonstrated in most of the in vivo and ex vivo systems studied so far. Cytotoxicity and immunogenicity are still a problem. Techniques for appropriate delivery of vector or cells into the appropriate location have not been perfected. Promoters used currently in gene transfer do not have precise control over gene expression, but new vectors are being developed that will allow cell-specific and controlled gene expression. The introduction of functional genes into the brains of patients with Parkinson disease may, for example, prove useful as a means to replace a defective gene, introduce a potentially neuroprotective or neurorestorative protein, or permit the physiological delivery of a deficient neurotransmitter. Recent observations suggest that the oral administration of currently available dopaminomimetics to relatively advanced parkinsonian patients leads to nonphysiological intermittent stimulation of striatal neurons that express dopamine receptors. Resultant activation of signal transduction pathways from these dopaminergic receptors on medium-sized GABAergic neurons apparently induces long-term potentiation of adjacent glutamatergic receptors of the N-methyl-D-aspartate subtype. Thus, the effects of dopaminergic drugs become modified in ways that favor the clinical appearance of response fluctuations and peakdose dyskinesias. In parkinsonian models, as well as in patients with Parkinson disease, continuous dopaminergic replacement tends to prevent or alleviate these adverse effects. By continuously maintaining appropriate cerebral dopamine concentrations, molecular techniques that stimulate an increase in the intrastriatal activity of tyrosine hydroxylase (the rate-limiting enzyme for dopamine synthesis) might be expected to palliate parkinsonian symptoms with less risk of the disabling consequences of current therapy. Clinical study of these approaches could also serve as initial, relatively simple, proof-of-principle evaluations of the safety and efficacy of genetic approaches to the treatment of basic disease processes in Parkinson disease. Among the various neurotrophic factors, glial cell line-derived neurotrophic factor is receiving the most attention for Parkinson disease therapy; its administration by gene therapy would be an ideal method of delivery. Glial cell linederived neurotrophic factor mrna is mainly expressed in neurons of the cortex, hippocampus, striatum, substantia nigra, thalamus, cerebellum, and spinal cord. Its synthesis is not restricted to dopaminergic areas. The widespread expression of glial cell line-derived neurotrophic factor throughout the adult brain suggests that its administration in Parkinson disease should be restricted to the altered structures in order to avoid possible deleterious side effects. The strategies for the application of gene therapy techniques to Parkinson disease treatment have expanded beyond the classical dopamine replacement toward the use of neurotrophic factors in enhancing cell function or preventing cell death. Rationale of gene therapy for Alzheimer disease. Potential gene therapy approaches to Alzheimer disease are based on neurotrophic factors and not neurotransmitters. The optimal method of gene therapy would be ex vivo involving implantation of genetically engineered cells secreting nerve growth factor. Naturally occurring age-related memory loss in rats can be reversed by grafting cells engineered to secrete nerve growth factor directly into the nucleus basalis magnocellularis. Grafting of nerve growth factor-producing fibroblasts has been shown to reduce behavioral deficits associated with lesions of the nucleus basalis magnocellularis in rats. Intraventricular transplants of polymer encapsulated fibroblasts secreting human nerve growth factor have been shown to provide trophic support to basal forebrain neurons in cynomolgus monkeys with unilateral transection of fornix. Rationale for gene therapy of Huntington disease. It has been reported that intrastriatal implantation of genetically engineered nerve growth factor-producing fibroblasts has a protective effect against excitotoxic insults. Rationale for gene therapy of amyotrophic lateral sclerosis. In cases associated with mutations in superoxide dismutase gene, the rational approach would be replacement of the defective gene by transfer of a wild-type superoxide dismutase gene. The patients with such genetic defects constitute only 5% of the cases, and no gene therapy has yet been developed. The strategies for gene therapy are based on the beneficial effects of neurotrophic factors in amyotrophic lateral sclerosis, and gene therapy by implantation of genetically engineered cells secreting neurotrophic factors is considered to be the best strategy at present.
References cited Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2(6):696-9. PMID 8640564 Allen PJ, Feigin A. Gene-based therapies in Parkinson's disease. Neurotherapeutics 2014;11(1):60-7. PMID 24129887 Azzouz M, Ralph GS, Storkebaum E, et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429(6990):413-7. PMID 15164063 Bartus RT, Brown L, Wilson A, et al. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis 2011;44(1):38-52. PMID 21704161 Bloch J, Bachoud-Levi AC, Deglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymerencapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004;15(10):968-75. PMID 15585112 Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009;73(20):1662-9. PMID 19828868 Cress DE. The need for regulatable vectors for gene therapy for Parkinson's disease. Exp Neurol 2008;209(1):30-3. PMID 17942096 Diaz-Nido J. NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Investig Drugs 2010;11:813-22. PMID 20571977 Drinkut A, Tereshchenko Y, Schulz JB, Bähr M, Kügler S. Efficient gene therapy for Parkinson's disease using astrocytes as hosts for localized neurotrophic factor delivery. Mol Ther 2012;20(3):534-43. PMID 22086235 El-Amouri SS, Zhu H, Yu J, Gage FH, Verma IM, Kindy MS. Neprilysin protects neurons against Abeta peptide toxicity. Brain Res 2007;1152:191-200. PMID 17459354 Evers MM, Pepers BA, van Deutekom JC, et al. Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One 2011;6(9):e24308. PMID 21909428 Fjord-Larsen L, Johansen JL, Kusk P, et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 2005;195(1):49-60. PMID 15919076 Hashimoto M, Rockenstein E, Mante M, et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 2004;11(23):1713-23. PMID 15483670 Huang B, Schiefer J, Sass C, Landwehrmeyer GB, Kosinki CM, Kochanek S. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum Gene Ther 2007;18(4):303-11. PMID 17472569 Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369(9579):2097-105. PMID 17586305 Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A 20116;108(49):E1339-48. PMID 22042871 Lewis TB, Glasgow JN, Harms AS, Standaert DG, Curiel DT. Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy. Viruses 2014;6(8):3293-310. PMID 25196484 Li Y, Wang J, Zhang S, Liu Z. Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease. J Neurosci Res 2015;93(9):1325-9. PMID 26096375 López-Tobón A, Castro-Álvarez JF, Piedrahita D, Boudreau RL, Gallego-Gómez JC, Cardona-Gómez GP. Silencing of CDK5 as potential therapy for Alzheimer's disease. Rev Neurosci 2011;22(2):143-52. PMID 21476938